Abstract
Diffuse alveolar hemorrhage (DAH) is a potentially life-threatening pulmonary manifestation that has been associated with various diseases. It is a medical emergency that requires prompt diagnosis and aggressive treatment. The clinical manifestations consist of hemoptysis, hypoxia, a drop in the hemoglobin level and new pulmonary infiltrates on chest X-ray. Infrequently, Systemic lupus erythematosus (SLE) and Antiphospholipid syndrome (APS) could be complicated by this severe pulmonary manifestation. The most common histologic lesion in SLE and Antiphospholipid Syndrome is pulmonary capillaritis. Corticosteroids with or without immunosuppressive agents such as cyclophosphamide are the mainstay of the therapy. Plasmapheresis, intravenous immunoglobulin or the newer biologic agents would be considered if there is a persistent lack of clinical response.
Keywords: Systemic lupus erythematosus, diffuse alveolar hemorrhage, antiphospholipid syndrome, pulmonary hemorrhage
Current Respiratory Medicine Reviews
Title: Diffuse Alveolar Hemorrhage, A Potentially Life-Threatening Manifestation in Systemic Lupus Erythematosus and the Antiphospholipid Syndrome
Volume: 5 Issue: 2
Author(s): Javier A. Cavallasca, Maria del Rosario Maliandi, Diego H. Goffredo and Gustavo G. Nasswetter
Affiliation:
Keywords: Systemic lupus erythematosus, diffuse alveolar hemorrhage, antiphospholipid syndrome, pulmonary hemorrhage
Abstract: Diffuse alveolar hemorrhage (DAH) is a potentially life-threatening pulmonary manifestation that has been associated with various diseases. It is a medical emergency that requires prompt diagnosis and aggressive treatment. The clinical manifestations consist of hemoptysis, hypoxia, a drop in the hemoglobin level and new pulmonary infiltrates on chest X-ray. Infrequently, Systemic lupus erythematosus (SLE) and Antiphospholipid syndrome (APS) could be complicated by this severe pulmonary manifestation. The most common histologic lesion in SLE and Antiphospholipid Syndrome is pulmonary capillaritis. Corticosteroids with or without immunosuppressive agents such as cyclophosphamide are the mainstay of the therapy. Plasmapheresis, intravenous immunoglobulin or the newer biologic agents would be considered if there is a persistent lack of clinical response.
Export Options
About this article
Cite this article as:
Cavallasca A. Javier, Maliandi del Rosario Maria, Goffredo H. Diego and Nasswetter G. Gustavo, Diffuse Alveolar Hemorrhage, A Potentially Life-Threatening Manifestation in Systemic Lupus Erythematosus and the Antiphospholipid Syndrome, Current Respiratory Medicine Reviews 2009; 5 (2) . https://dx.doi.org/10.2174/157339809788189987
DOI https://dx.doi.org/10.2174/157339809788189987 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Erythropoietin in Heart Failure and Other Cardiovascular Diseases: Hematopoietic and Pleiotropic Effects
Current Drug Targets - Cardiovascular & Hematological Disorders The Successful Treatment of Pulmonary Embolism as a Complication after Uterine Fibroid Embolization (Case Report)
Current Women`s Health Reviews Radioembolization of Hepatocellular Carcinoma
Current Drug Discovery Technologies Tailored Angiogenesis Inhibition in Cancer Therapy: Respecting the Heart to Improve the Net Outcome
Current Signal Transduction Therapy Evaluation of Two Recombinant Plasminogen Activators in Massive Pulmonary Embolism Model and Potato Carboxypeptidase Inhibitor (PCI) role in Inhibition of Thrombin Activatable Fibrinolysis Inhibitor TAFIa in Lungs
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Bivalirudin or Heparin Treatment During Transcatheter Valve Interventions: Where are we Now?
Current Pharmaceutical Design Prostacyclin Analogues: Prevention of Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Risk of Bleeding Related to Antithrombotic Treatment in Cardiovascular Disease
Current Pharmaceutical Design PKC Delta and Epsilon in Drug Targeting and Therapeutics
Recent Patents on DNA & Gene Sequences Recent Research Developments in the Direct Inhibition of Coagulation Proteinases – Inhibitors of the Initiation Phase
Cardiovascular & Hematological Agents in Medicinal Chemistry Efficacy and Safety of the Combination of Docetaxel (Taxotere®) with Targeted Therapies in the Treatment of Solid Malignancies
Current Drug Targets ESVS Guidelines: Section B - Diagnosis and Investigation of Patients with Carotid Stenosis
Current Vascular Pharmacology Blood Pressure Lowering Treatment in Patients with Carotid Artery Stenosis
Current Hypertension Reviews Pharmacotherapy and HDL Cholesterol
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Antiangiogenic Therapy in Malignant Glioma: Promise and Challenge
Current Pharmaceutical Design Inflammation-Mediating Proteases: Structure, Function in (Patho) Physiology and Inhibition
Protein & Peptide Letters Cardiotoxicity of Molecularly Targeted Agents
Current Cardiology Reviews Detection of a Left Atrial Thrombus Under Fondaparinux Treatment: A Case Report
Current Drug Safety Laboratory Monitoring or Measurement of Direct Oral Anticoagulants (DOACs): Advantages, Limitations and Future Challenges
Current Drug Metabolism Tamoxifen in the Treatment of Hepatocellular Carcinoma: 5-Year Results of the CLIP-1 Multicentre Randomised Controlled Trial
Current Pharmaceutical Design